{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:03:26Z","timestamp":1696593806939},"reference-count":35,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2014,9,23]],"date-time":"2014-09-23T00:00:00Z","timestamp":1411430400000},"content-version":"unspecified","delay-in-days":571,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:sec id=\"S0317167100013809_abs1\"><jats:title>Background:<\/jats:title><jats:p>Bevacizumab, a humanized recombinant anti-vascular endothelial growth factor antibody, was approved in Canada in 2010 for the treatment of high-grade glioma. We report the effectiveness and safety of bevacizumab in the treatment of patients with recurrent high-grade gliomas at a single institution.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100013809_abs2\"><jats:title>Methods:<\/jats:title><jats:p>Twenty-seven consecutive patients with high-grade glioma (anaplastic glioma and glioblastoma) at first or subsequent relapse were treated with bevacizumab alone or in combination with chemotherapy. The primary endpoint was progression-free survival (PFS) and secondary endpoints were objective response rate, six month PFS, overall survival (OS), and safety profile.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100013809_abs3\"><jats:title>Results:<\/jats:title><jats:p>The clinical benefit rate (complete and partial responses plus stable disease) was 59%. Median PFS was 4.3 (95% CI, 3.0-10.9) months, with a six month PFS rate of 43%. Median OS after current relapse was 8.9 (95% CI, 5.8-not reached) months. Ten episodes of grade 3\/4 adverse events were observed in nine patients, including fatigue (n = 3), thrombocytopenia (n = 4), and myelotoxicity, febrile neutropenia, and pulmonary embolism (each n = 1).<\/jats:p><\/jats:sec><jats:sec id=\"S0317167100013809_abs4\"><jats:title>Conclusions:<\/jats:title><jats:p>We consider the efficacy and safety profile of bevacizumab is comparable to other cohorts of patients treated for recurrent high-grade glioma at other international institutions.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s0317167100013809","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T14:59:25Z","timestamp":1418396365000},"page":"241-246","source":"Crossref","is-referenced-by-count":5,"title":["Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital"],"prefix":"10.1017","volume":"40","author":[{"given":"Solmaz","family":"Sahebjam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgenia","family":"Garoufalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Guiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Muanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Del Maestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Petrecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Kavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,9,23]]},"reference":[{"key":"S0317167100013809_ref027","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2008.04.003"},{"key":"S0317167100013809_ref030","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp591"},{"key":"S0317167100013809_ref017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3055"},{"key":"S0317167100013809_ref005","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0027"},{"key":"S0317167100013809_ref025","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.2012","article-title":"Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: a multicenter Italian study","volume":"27","author":"Soffietti","year":"2009","journal-title":"J Clin Oncol."},{"key":"S0317167100013809_ref009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"S0317167100013809_ref014","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2309"},{"key":"S0317167100013809_ref029","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq099"},{"key":"S0317167100013809_ref020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"S0317167100013809_ref024","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802537924"},{"key":"S0317167100013809_ref034","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0105"},{"key":"S0317167100013809_ref013","first-page":"5565","article-title":"Anti-vascular endothelial growth factor treatment augments tumour radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res."},{"key":"S0317167100013809_ref035","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-011-0565-x"},{"key":"S0317167100013809_ref007","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res."},{"key":"S0317167100013809_ref001","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903052764"},{"key":"S0317167100013809_ref018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721"},{"key":"S0317167100013809_ref028","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.2011","article-title":"RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)","volume":"27","author":"Gilbert","year":"2009","journal-title":"J Clin Oncol."},{"key":"S0317167100013809_ref022","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1316"},{"key":"S0317167100013809_ref032","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e12552"},{"key":"S0317167100013809_ref031","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e12522"},{"key":"S0317167100013809_ref021","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-011-0130-0"},{"key":"S0317167100013809_ref002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"S0317167100013809_ref026","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605412"},{"key":"S0317167100013809_ref023","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0037"},{"key":"S0317167100013809_ref012","doi-asserted-by":"publisher","DOI":"10.1593\/neo.08928"},{"key":"S0317167100013809_ref008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021491"},{"key":"S0317167100013809_ref011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"S0317167100013809_ref004","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-005-9097-6"},{"key":"S0317167100013809_ref006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081"},{"key":"S0317167100013809_ref016","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000304121.57857.38"},{"key":"S0317167100013809_ref010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"S0317167100013809_ref019","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0121"},{"key":"S0317167100013809_ref015","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2440"},{"key":"S0317167100013809_ref003","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.9.704"},{"key":"S0317167100013809_ref033","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e12553"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167100013809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T16:53:43Z","timestamp":1690736023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167100013809\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0317167100013809"],"URL":"https:\/\/doi.org\/10.1017\/s0317167100013809","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}